1. Majoni SW, Abeyaratne A. Renal transplantation in indigenous Australians of the
Northern Territory: closing the gap. Internal medicine journal. 2013;43(10):1059-66.
2. Lawton PD, Cunningham J, Zhao Y, Gray NA, Chatfield MD, Baade PD, Murali, K.
Jose, M. D. Survival of Indigenous Australians receiving renal replacement therapy:
closing the gap? The Medical journal of Australia. 2015;202(4):200-4.
3. Rogers NM, Lawton PD, Jose MD. Kidney transplant outcomes in the indigenous population
in the Northern Territory of Australia. Transplantation. 2006;82(7):882-6.
4. Rogers NM, Lawton PD, Jose MD. Plasma cell infiltrates and renal allograft outcomes
in indigenous and non-indigenous people of the Northern Territory of Australia. Nephrology
(Carlton, Vic). 2011;16(8):777-83.
5. Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Current opinions on therapeutic
drug monitoring of immunosuppressive drugs. Clinical therapeutics. 1999;21(10):1632-52.
6. Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel, David
Armitage, J. Jain, A. McCauley, J. Selby, R. Starzl, T. E. . Adverse Effects Associated With the Use of FK 506. Transplantation proceedings.
1991;23(6):3105-8.
7. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians, U.
Winkler, M. Fitzsimmons, W. E. Lieberman, R. . Consensus document: therapeutic monitoring
of tacrolimus (FK-506). Therapeutic drug monitoring. 1995;17(6):606-14.
8. Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo,
R. R.
Grinyo, J. Frei, U. Vanrenterghem, Y. Daloze, P. Halloran, P. . Calcineurin inhibitor
minimization in the Symphony study: observational results 3 years after transplantation.
American journal of transplantation : official journal of the American Society of
Transplantation and the American Society of Transplant Surgeons. 2009;9(8):1876-85.
9. Gagliardo F, Dole K, Majoni SW . Immunosuppressive drug assaying: A challenge for
renal transplantation in the Northern Territory, Australia. In: D.K., editor.: AMJ;
2016. p. 89-193.
10. Insert. TP. Abbott Laboratories, Diagnostics Division, Abbott Park, IL, Architect
System, Tacrolimus Ref 1 L77. April 2009 © 2006, 2009 Abbott Laboratories.
11. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers,
D.
Le Meur, Y. Marquet, P. Oellerich, M. Thervet, E. Toenshoff, B. Undre, N. Weber, L.
T. Westley, I. S. Mourad, M. . Opportunities to optimize tacrolimus therapy in solid
organ transplantation: report of the European consensus conference. Therapeutic drug
monitoring. 2009;31(2):139-52.
12. Koal T, Deters M, Casetta B, Kaever V. Simultaneous determination of four immunosuppressants
by means of high speed and robust on-line solid phase extraction-high performance
liquid chromatography-tandem mass spectrometry. Journal Of Chromatography B, Analytical
Technologies In The Biomedical And Life Sciences. 2004;805(2):215-22.
13. Report. E-o-C. Special Therapeutic Drugs and Antibiotics Program Cycle: 67, 29
January - 18 June 2018. RCPAQAP 2018.
14. Gounden V, Soldin SJ. Tacrolimus Measurement: Building a Better Immunoassay. 2014;60(4):575-6.
15. Murthy JN, Davis DL, Yatscoff RW, Soldin SJ. Tacrolimus metabolite cross-reactivity
in different tacrolimus assays. Clinical biochemistry. 1998;31(8):613-7.
16. Christians U, Kruse C, Kownatzki R, Schiebel HM, Schwinzer R, Sattler M, Schottmann,
R.
Linck, A. Almeida, V. M. Braun, F. . Measurement of FK 506 by HPLC and isolation
and characterization of its metabolites. Transplant Proc. 1991;23(1 Pt 2):940-1.
17. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacology
& therapeutics. 1993;57(2-3):291-345.
18. Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF. Tacrolimus
(FK506) metabolite patterns in blood from liver and kidney transplant patients. Clinical
chemistry. 1996;42(9):1426-32.
19. Chitnis SD, Ogasawara K, Schniedewind B, Gohh RY, Christians U, Akhlaghi F. Concentration
of tacrolimus and major metabolites in kidney transplant recipients as a function
of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica; the fate
of foreign compounds in biological systems. 2013;43(7):641-9.
20. Levine DM, Maine GT, Armbruster DA, Mussell C, Buchholz C, O'Connor G, Tuck, V.
Johnston, A. Holt, D. W. . The need for standardization of tacrolimus assays. Clinical
chemistry. 2011;57(12):1739-47.
21. Annesley TM, McKeown DA, Holt DW, Mussell C, Champarnaud E, Harter L, Calton,
L. J. Mason, D. S. . Standardization of LC-MS for therapeutic drug monitoring of tacrolimus.
Clinical chemistry. 2013;59(11):1630-7.
22. Seger C, Shipkova M, Christians U, Billaud EM, Wang P, Holt DW, Brunet, Mercè
Kunicki, Pawel K. Pawinski, Thomasz Langman, Loralie J. Marquet, Pierre Oellerich,
Michael Wieland, Eberhard Wallemacq, Pierre Assuring the Proper Analytical Performance
of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice:
Recommendations of the International Association of Therapeutic Drug Monitoring and
Clinical Toxicology Immunosuppressive Drug Scientific Committee. 2016;38(2):170-89.
23. Insert. TC. Abbott Laboratories, Diagnostics Division, Abbott Park, IL, Architect
System, Tacrolimus Ref 1L77-01. Revised October 2014. ©2006, 2014 Abbott Laboratories.
24. De BK, Jimenez E, De S, Sawyer JC, McMillin GA. Analytical performance characteristics
of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem
mass spectrometry (LC-MS/MS) and Abbott IMx methods. Clin Chim Acta. 2009;410(1-2):25-30.